Get the Stockscreener App
8.60
1.06%
0.09
Pre-market:
8.68
0.08
+0.93%
Bioventus Inc stock is traded at $8.60, with a volume of 631.92K.
It is up +1.06% in the last 24 hours and down -18.71% over the past month.
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.
See More
Previous Close:
$8.51
Open:
$8.54
24h Volume:
631.92K
Relative Volume:
1.14
Market Cap:
$582.63M
Revenue:
$568.09M
Net Income/Loss:
$27.27M
P/E Ratio:
26.25
EPS:
0.3276
Net Cash Flow:
$71.41M
1W Performance:
-3.91%
1M Performance:
-18.71%
6M Performance:
+14.67%
1Y Performance:
+29.91%
1-Day Range:
$8.45
$8.68
1-Week Range:
$8.45
$9.385
52-Week Range:
$5.81
$11.25
Bioventus Inc Stock (BVS) Company Profile
Name
Bioventus Inc
Sector
Industry
Phone
(919) 474-6700
Address
4721 EMPEROR BOULEVARD, SUITE 100, DURHAM
Compare BVS vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BVS
Bioventus Inc
|
8.60 | 582.63M | 568.09M | 27.27M | 71.41M | 0.3276 |
ABT
Abbott Laboratories
|
88.67 | 154.45B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.94 | 118.05B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
80.38 | 103.20B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
46.76 | 69.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.28 | 49.68B | 6.30B | 1.07B | 1.09B | 1.8406 |
Bioventus Inc Stock (BVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-26 | Initiated | CJS Securities | Market Outperform |
| Feb-09-26 | Initiated | Barrington Research | Outperform |
| Jul-07-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-17-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-07-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-09-23 | Upgrade | Craig Hallum | Hold → Buy |
| Nov-22-22 | Downgrade | Craig Hallum | Buy → Hold |
| Nov-09-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Nov-09-22 | Downgrade | JP Morgan | Overweight → Underweight |
| Mar-15-22 | Initiated | Craig Hallum | Buy |
| Nov-15-21 | Resumed | Morgan Stanley | Overweight |
| Nov-10-21 | Resumed | JP Morgan | Overweight |
| Jul-01-21 | Downgrade | Goldman | Buy → Neutral |
| Mar-08-21 | Initiated | Canaccord Genuity | Buy |
| Mar-08-21 | Initiated | Goldman | Buy |
| Mar-08-21 | Initiated | JP Morgan | Overweight |
| Mar-08-21 | Initiated | Morgan Stanley | Overweight |
View All
Bioventus Inc Stock (BVS) Latest News
Canaccord reiterates Bioventus stock rating on growth strategy By Investing.com - Investing.com Canada
Bioventus Inc. (BVS) Q1 2026 Earnings: Strong EPS Beat Despite Stock DeclineEarnings Miss Streak - newsline.com
Bioventus highlights PNS, PRP growth as cash flow improves and debt falls - MSN
Are Investors Undervaluing Bioventus (BVS) Right Now? - Yahoo Finance
Bioventus (BVS) Edges Lower as Stock Tests Support ZoneGamma Squeeze - newsline.com
Bioventus Highlights PNS, PRP Growth as Cash Flow Improves and Debt Falls - sharewise.com
Bioventus Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Technical Reactions to BVS Trends in Macro Strategies - Stock Traders Daily
BVS SEC FilingsBioventus Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Bioventus (BVS) director and 10% owner reports RSU grant and vesting-related share exercise - Stock Titan
Bioventus (NASDAQ: BVS) director Sutter awarded 25,146 RSUs and exercises 32,282 shares - Stock Titan
Bioventus (BVS) director granted RSUs and exercises prior awards - Stock Titan
Bioventus (BVS) director exercises RSUs and holds 148,892 shares - Stock Titan
Bioventus (BVS) director receives 25,146 RSUs and converts 32,282 into shares - Stock Titan
Bioventus (BVS) director McMurry-Heath gains shares via RSU vesting and new grant - Stock Titan
[Form 4] Bioventus Inc. Insider Trading Activity - Stock Titan
Bioventus (BVS) director Hawkins granted 30,994 RSUs and exercises 39,789 into shares - Stock Titan
Bioventus (BVS) director granted 25,146 RSUs and exercises 32,282 into shares - Stock Titan
Bioventus (BVS) director Pat Beyer receives 25,146 RSUs and converts 32,282 into Class A shares - Stock Titan
Bioventus Q1 2026 slides: earnings beat drives guidance raise - Investing.com
Bioventus Shareholders Back Directors and Auditor at 2026 Meeting - TipRanks
Bioventus (BVS) 2026 meeting re-elects full board and ratifies auditor - Stock Titan
Bioventus Inc. (BVS) Gains 1.75% as Stock Tests Key Resistance ZoneSingle Stock ETF - newsline.com
Bioventus (BVS) Q1 2026 Earnings Transcript - AOL.com
After Plunging 22% in 4 Weeks, Here's Why the Trend Might Reverse for Bioventus (BVS) - Yahoo Finance
Bioventus (BVS) may find a bottom soon, here's why you should buy the stock now - MSN
Bioventus to Present at the Goldman Sachs 47TH Annual Global Healthcare Conference - The Manila Times
Watch Bioventus' CFO in a live Goldman Sachs healthcare fireside chat - Stock Titan
Transcript: Bioventus Q1 2026 Earnings Conference Call - Benzinga
BVS Q1 2026 Earnings: Strong EPS Beat Overshadowed by Market SkepticismAnalyst Coverage Count - The Legal Advocate
BVS Q1 2026 Earnings: EPS Beats Estimates by 52.3% Despite Stock DeclineEarnings Analysis - The Legal Advocate
Bioventus (BVS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - sharewise.com
Bioventus Inc. (BVS) Holds Steady Near Support as Consolidation PersistsBlock Trade Flow - newsline.com
Number of shareholders of Bioventus Inc. – NASDAQ:BVS - TradingView
Is Bioventus (BVS) stock undervalued right now? - MSN
Craig-Hallum Maintains Bioventus(BVS.US) With Buy Rating - Moomoo
Bioventus (BVS) Q1 2026 Earnings: Strong EPS Beat Amidst Market SkepticismDiluted EPS Report - The Legal Advocate
BVS Maintained by Barrington Research -- Price Target at $14.00 - GuruFocus
Bioventus Inc.Class A Common Stock (NQ: BVS - The Chronicle-Journal
Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It - Benzinga
Bioventus Is Maintained at Outperform by Barrington Research - Moomoo
Bioventus Inc. Files Form 8-K: Corporate Details, Stock Information, and SEC Compliance for May 2026 - Minichart
FDA reclassifies Bioventus bone growth stimulator; company maintains 2026 outlook - Investing.com UK
FDA reclassifies Bioventus bone growth stimulator; company maintains 2026 outlook By Investing.com - Investing.com South Africa
Bioventus Inc stated in a filing with the SEC that expected adjustments to reimbursement policies related to the Exogen bone healing system are not anticipated to have a material impact on the company’s financial position for fiscal year 2026. - Bitget
According to documents submitted to the U.S. Securities and Exchange Commission, SEACOR Marine Holdings Inc. expects its newly built platform supply vessels to be delivered successively in the fourth quarter of 2026 and the first quarter of 2027. - Bitget
GE Vernova Inc. announces the acquisition of Robotech Automation to accelerate advancements in its robotics and automation capabilities. - Bitget
According to documents submitted to the U.S. Securities and Exchange Commission, the U.S. Food and Drug Administration completed the reclassification of Bioventus Inc.'s Exogen ultrasound bone healing system on April 16, 2026. - Bitget
FDA reclassifies bone growth stimulators; Bioventus says 2026 guidance unchanged - TradingView
CMS reimbursement shifts leave Bioventus (NASDAQ: BVS) 2026 guidance intact - Stock Titan
Is Bioventus (BVS) Stock Undervalued Right Now? - Yahoo Finance
Bioventus Inc Stock (BVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):